TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tvardi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.97−0.04 (-3.96%)
Close on Oct 19, 2026
- Market cap
- $9.10M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
16.7%
2M of 13M shares
Institutional holders
58
13 new, 20 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sporos Bioventures LLC | 837,636 | 8.95% | 13G (passive) | Apr 15, 2025 |
| Solas Partners II, LLC | 761,287 | 8.10% | 13G (passive) | Apr 15, 2025 |
| Vifor (International) Ltd. | 7,396,770 | 13.50% | 13D (active) amendment | Dec 17, 2024 |
| Slate Path Capital LP | 704,118 | 7.50% | 13G (passive) | Jun 30, 2025 |
| David J. Tweardy | 652,398 | 7.00% | 13G (passive) | Apr 15, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TVRD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Slate Path Capital LP | 704,118 | 5.28% | $1.34M | – | 0.02% |
| Vanguard Capital Management LLC | 344,382 | 2.58% | $654.33K | −326 | 0.00% |
| American Financial Group Inc | 223,659 | 1.68% | $424.95K | – | 0.15% |
| UBS Group AG | 111,133 | 0.83% | $211.15K | +60,679 | 0.00% |
| Silvercrest Asset Management Group LLC | 101,034 | 0.76% | $191.97K | – | 0.00% |
| BlackRock, Inc. | 95,478 | 0.72% | $181.41K | −292,597 | 0.00% |
| Renaissance Technologies LLC | 91,409 | 0.69% | $173.68K | −691 | 0.00% |
| Geode Capital Management, LLC | 90,350 | 0.68% | $171.74K | −91,989 | 0.00% |
| Morgan Stanley | 77,845 | 0.58% | $147.91K | +4,951 | 0.00% |
| Duncan Williams Asset Management, LLC | 63,241 | 0.47% | $120.16K | – | 0.03% |
| Vanguard Fiduciary Trust Co | 44,710 | 0.34% | $84.95K | −2,162 | 0.00% |
| Russell Investments Group, Ltd. | 43,228 | 0.32% | $82.13K | +19,921 | 0.00% |
| State Street Corp | 33,900 | 0.25% | $64.41K | −63,331 | 0.00% |
| Susquehanna International Group, Llp | 33,165 | 0.25% | $63.01K | New | 0.00% |
| Aqr Capital Management LLC | 27,096 | 0.20% | $51.48K | −15,096 | 0.00% |
| Northern Trust Corp | 21,836 | 0.16% | $41.49K | −27,245 | 0.00% |
| Savant Capital, LLC | 19,462 | 0.15% | $49.43K | New | 0.00% |
| Gsa Capital Partners Llp | 17,885 | 0.13% | $34 | New | 0.00% |
| Diadema Partners LP | 16,607 | 0.12% | $31.55K | New | 0.00% |
| XTX Topco Ltd | 14,868 | 0.11% | $28.25K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 58 | 2M | 16.7% | 13 / 7 | 24 / 20 | 0M | 1M |
| Q1 2026 | 67 | 3M | 20.3% | 16 / 19 | 17 / 11 | 1M | 0M |
| Q4 2025 | 64 | 3M | 21.2% | 14 / 28 | 7 / 15 | 1M | 1M |
| Q3 2025 | 65 | 3M | 19.5% | 23 / 21 | 6 / 7 | 1M | 0M |
| Q2 2025 | 49 | 2M | 14.4% | 49 / 0 | 0 / 0 | 2M | 0M |
| Q4 2023 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TVRD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 258,426 | 1.94% | $491.01K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 85,956 | 0.64% | $163.32K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 50,517 | 0.38% | $170.75K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 30,558 | 0.23% | $103.29K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 14,439 | 0.11% | $48.80K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 12,181 | 0.09% | $41.17K | 0.00% | May 31, 2026 |
| iShares Russell 2000 ETF | 8,873 | 0.07% | $16.86K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 6,450 | 0.05% | $21.80K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Value Index Fund | 3,820 | 0.03% | $12.91K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 2,607 | 0.02% | $4.95K | 0.00% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Value Fund | 1,975 | 0.01% | $3.75K | 0.00% | Jun 30, 2026 |
| Small Cap Index Fund | 1,388 | 0.01% | $4.69K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 1,225 | 0.01% | $2.33K | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 471 | 0.00% | $1.59K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 402 | 0.00% | $764 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Imran Nizamudin Alibhai | Chief Executive Officer, Director | – | – | Feb 2, 2026 |
| Christopher Posner | PRESIDENT AND CEO, Director | 13,109 | 0.10% | Mar 4, 2025 |
| Avi Daniel Conn | Chief Financial Officer | – | – | Feb 2, 2026 |
| John Saewook M.D. Kauh | Chief Medical Officer | – | – | Feb 2, 2026 |
| Stephen Paul O'Brien | Principal Accounting Officer | – | – | Feb 2, 2026 |
| Yixin Chen | VP, Chem, Mfg and Ctrls | – | – | Apr 21, 2025 |
| Jeffrey Leroy Larson | SVP, Research & Development | – | – | Apr 21, 2025 |
| Scott Terrillion | SEC'Y; CHIEF COMPLIANCE & G.C. | 7,190 | 0.05% | Mar 4, 2025 |
| Michael S. Wyzga | Director | – | – | Jun 11, 2026 |
| Cynthia Smith | Director | – | – | Jun 11, 2026 |
| Susan Ph.D. Shiff | Director | 202,085 | 1.52% | Jun 11, 2026 |
| Wallace L. Hall Jr | Director | 246,756 | 1.85% | Jun 11, 2026 |
| Sujal Shah | Director | – | – | Jun 11, 2026 |
| Shaheen Wirk | Director | 443,385 | 3.32% | May 2, 2025 |
| Samuel David Tweardy | 10% owner | 0 | – | Aug 5, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Samuel David Tweardy 10% owner | Jul 7, 2025 | Other | −315,658 | – | – | 0 |
| Samuel David Tweardy 10% owner | Jul 7, 2025 | Other | −315,658 | – | – | 0 |
| Shaheen Wirk Director | Apr 15, 2025 | Award | +176,030 | – | – | 176,030 |
| Shaheen Wirk Director | Apr 15, 2025 | Award | +263,164 | – | – | 263,164 |
| Wallace L. Hall Jr Director | Apr 15, 2025 | Award | +202,044 | – | – | 202,044 |
| Wallace L. Hall Jr Director | Apr 15, 2025 | Award | +44,712 | – | – | 44,712 |
| Wallace L. Hall Jr Director | Apr 15, 2025 | Other | +44,712 | – | – | 44,712 |
| Wallace L. Hall Jr Director | Apr 15, 2025 | Other | +202,044 | – | – | 202,044 |
| Shaheen Wirk Director | Apr 15, 2025 | Other | +176,030 | – | – | 176,030 |
| Shaheen Wirk Director | Apr 15, 2025 | Other | +263,164 | – | – | 263,164 |
| Shaheen Wirk Director | Apr 15, 2025 | Award | +4,191 | – | – | 4,191 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 28, 2025 | Sale(10b5-1 plan) | −583 | $4.75 | $2.77K | 13,109 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 28, 2025 | Sale(10b5-1 plan) | −163 | $4.76 | $776 | 7,190 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 4, 2025 | Sale(10b5-1 plan) | −372 | $4.72 | $1.76K | 13,692 |
| Christopher Posner PRESIDENT AND CEO, Director | Nov 4, 2024 | Sale(10b5-1 plan) | −3,668 | $0.29 | $1.06K | 168,768 |
| Christopher Posner PRESIDENT AND CEO, Director | Aug 1, 2024 | Sale(10b5-1 plan) | −4,149 | $0.35 | $1.45K | 172,436 |
| Moltke Lisa von Director | Jun 4, 2024 | Award | +150,647 | – | – | 183,009 |
| Martin Vogelbaum Director | Jun 4, 2024 | Award | +301,295 | – | – | 411,007 |
| Jeffrey L. Ives Director | Jun 4, 2024 | Award | +150,647 | – | – | 198,485 |
| Helen M. Boudreau Director | Jun 4, 2024 | Award | +150,647 | – | – | 150,647 |
| Susan Ph.D. Shiff Director | Jun 4, 2024 | Award | +150,647 | – | – | 202,085 |
| Christopher Posner PRESIDENT AND CEO, Director | May 2, 2024 | Sale(10b5-1 plan) | −3,936 | $0.75 | $2.95K | 176,585 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Apr 5, 2024 | Sale(10b5-1 plan) | −2,753 | $0.83 | $2.28K | 88,247 |
| Joana Goncalves CHIEF MEDICAL OFFICER | Apr 5, 2024 | Sale(10b5-1 plan) | −2,753 | $0.83 | $2.28K | 53,365 |
| Joana Goncalves CHIEF MEDICAL OFFICER | Feb 29, 2024 | Sale(10b5-1 plan) | −3,293 | $0.89 | $2.93K | 56,118 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 29, 2024 | Sale(10b5-1 plan) | −5,834 | $0.89 | $5.19K | 180,521 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 29, 2024 | Sale(10b5-1 plan) | −3,293 | $0.89 | $2.93K | 91,000 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 8, 2024 | Sale(10b5-1 plan) | −35,575 | $0.53 | $18.85K | 186,355 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 1, 2024 | Sale(10b5-1 plan) | −4,981 | $0.55 | $2.74K | 221,930 |
| Christopher Posner PRESIDENT AND CEO, Director | Feb 1, 2024 | Award | +62,500 | – | – | 226,911 |
| Joana Goncalves CHIEF MEDICAL OFFICER | Feb 1, 2024 | Award | +13,500 | – | – | 67,181 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 1, 2024 | Award | +13,500 | – | – | 102,063 |
| Frederique Ph.D. Menzaghi CHIEF SCIENTIFIC OFF,SVP-R&D | Feb 1, 2024 | Award | +13,500 | – | – | 167,247 |
| Ryan D. Maynard CHIEF FINANCIAL OFFICER | Feb 1, 2024 | Award | +13,500 | – | – | 13,500 |
| Christopher Posner President and CEO, Director | Nov 2, 2023 | Sale(10b5-1 plan) | −3,796 | $1.22 | $4.63K | 164,411 |
| Christopher Posner President and CEO, Director | Aug 3, 2023 | Sale(10b5-1 plan) | −4,307 | $3.07 | $13.22K | 168,207 |
| Frederique Ph.D. Menzaghi Chief Scientific Off,SVP-R&D | Jun 23, 2023 | Sale(10b5-1 plan) | −2,993 | $3.51 | $10.51K | 153,747 |
| Joana Goncalves Chief Medical Officer | Jun 23, 2023 | Sale(10b5-1 plan) | −2,723 | $3.51 | $9.56K | 53,681 |
| Scott Terrillion Sec'y; Chief Compliance & G.C. | Jun 23, 2023 | Sale(10b5-1 plan) | −2,483 | $3.51 | $8.72K | 88,563 |
| Harrison M. Bains Jr Director | Jun 1, 2023 | Award | +32,362 | – | – | 57,438 |
| Susan Ph.D. Shiff Director | Jun 1, 2023 | Award | +32,362 | – | – | 51,438 |
| Martin Vogelbaum Director | Jun 1, 2023 | Award | +64,724 | – | – | 109,712 |
| Jeffrey L. Ives Director | Jun 1, 2023 | Award | +32,362 | – | – | 47,838 |
| Moltke Lisa von Director | Jun 1, 2023 | Award | +32,362 | – | – | 32,362 |
| Christopher Posner President and CEO, Director | May 5, 2023 | Sale(10b5-1 plan) | −3,869 | $4.40 | $17.02K | 172,514 |
| Joana Goncalves Chief Medical Officer | Apr 4, 2023 | Sale(10b5-1 plan) | −2,481 | $4.91 | $12.18K | 56,404 |
| Scott Terrillion Sec'y; Chief Compliance & G.C. | Apr 4, 2023 | Sale(10b5-1 plan) | −2,481 | $4.91 | $12.18K | 91,046 |
| Frederique Ph.D. Menzaghi Chief Scientific Off,SVP-R&D | Apr 4, 2023 | Sale(10b5-1 plan) | −2,733 | $4.91 | $13.42K | 156,740 |
| Frederique Ph.D. Menzaghi Chief Scientific Off,SVP-R&D | Mar 3, 2023 | Sale(10b5-1 plan) | −6,802 | $9.71 | $66.05K | 159,473 |
| Christopher Posner President and CEO, Director | Mar 3, 2023 | Sale(10b5-1 plan) | −5,987 | $9.71 | $58.13K | 176,383 |
| Joana Goncalves Chief Medical Officer | Mar 3, 2023 | Sale(10b5-1 plan) | −6,221 | $9.71 | $60.41K | 58,885 |
| Scott Terrillion Sec'y; Chief Compliance & G.C. | Mar 3, 2023 | Sale(10b5-1 plan) | −6,256 | $9.71 | $60.75K | 93,527 |
| Joana Goncalves Chief Medical Officer | Feb 16, 2023 | Sale(10b5-1 plan) | −2,265 | $10.20 | $23.10K | 65,106 |
| Ryan D. Maynard CHIEF FINANCIAL OFFICER | Feb 8, 2023 | Sale(10b5-1 plan) | −5,488 | $0.53 | $2.91K | 8,012 |
| Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | Feb 8, 2023 | Sale(10b5-1 plan) | −7,770 | $0.53 | $4.12K | 94,293 |
| Joana Goncalves CHIEF MEDICAL OFFICER | Feb 8, 2023 | Sale(10b5-1 plan) | −7,770 | $0.53 | $4.12K | 59,411 |
| Christopher Posner President and CEO, Director | Feb 2, 2023 | Sale(10b5-1 plan) | −4,191 | $11.80 | $49.45K | 182,370 |
| Joana Goncalves Chief Medical Officer | Jan 17, 2023 | Sale(10b5-1 plan) | −2,265 | $10.81 | $24.48K | 67,371 |
| Joana Goncalves Chief Medical Officer | Dec 29, 2022 | Sale(10b5-1 plan) | −2,265 | $10.18 | $23.06K | 69,636 |
| Frederique Ph.D. Menzaghi Chief Scientific Off,SVP-R&D | Dec 21, 2022 | Sale(10b5-1 plan) | −3,506 | $11.27 | $39.51K | 166,275 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.